Axsome Therapeutics (NASDAQ: AXSM) announced that the first patient has been dosed in the SUMMIT Phase 3 trial evaluating AXS-05 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE